Skip to main content
Top
Published in: BMC Cancer 1/2024

Open Access 01-12-2024 | Research

Temporal trend in hospitalizations for malignant neoplasm and benign neoplasm: a nationwide study, China, 2004–2020

Authors: Xinqiang Zhang, Yuanyuan Li, Guifang Zhang, Changsheng Ma, Bo Liu, Yong Yin

Published in: BMC Cancer | Issue 1/2024

Login to get access

Abstract

The increasing cancer burden calls for reliably assessed changes in the hospitalizations for tumors over time and space in China. This study evaluated trends in hospitalization rate, in-hospital mortality, length of stay (LOS), and medical costs for malignant and benign neoplasms. Data were derived from China Health Statistical Yearbooks from 2004 to 2020. Temporal trends in hospitalization rates and in-hospital mortality rates were assessed through the Cochran-Armitage Test. We used the linear model with continuous variables to test for the trend. The malignant neoplasm hospitalization rate increased from 1.1‰ to 5.8‰ and the benign neoplasm increased from 1.0‰ to 2.0‰. The in-hospital mortality rate due to malignant neoplasm and benign neoplasm decreased from 5.11 to 2.87% (P for trend < 0.001) and 0.14–0.01% (P for trend < 0.001), respectively. Among all patients hospitalized with malignant neoplasm, the average cost per hospitalization significantly increased during the study period (P for trend < 0.001), adjusted for the Consumer Price Index. However, the average LOS gradually decreased (P for trend < 0.001). In line with the trend of malignant neoplasm, the average cost per hospitalization increased significantly among all patients hospitalized for benign neoplasm (P for trend < 0.001), and the average LOS showed a steady downward trend (P for trend < 0.001). We found upward trends in hospitalization rates, and medical costs in neoplasms. By contrast, substantial decreases in in-hospital mortality and LOS. The hospitalization rate gap between urban and rural areas is narrowed.
Literature
1.
go back to reference Cao M, Li H, Sun D, Chen W. Cancer burden of major cancers in China: a need for sustainable actions. Cancer Commun (Lond). 2020;40:205–10.CrossRefPubMed Cao M, Li H, Sun D, Chen W. Cancer burden of major cancers in China: a need for sustainable actions. Cancer Commun (Lond). 2020;40:205–10.CrossRefPubMed
2.
go back to reference Bray F, Laversanne M, Weiderpass E, Soerjomataram I. The ever-increasing importance of cancer as a leading cause of premature death worldwide. Cancer. 2021;127:3029–30.CrossRefPubMed Bray F, Laversanne M, Weiderpass E, Soerjomataram I. The ever-increasing importance of cancer as a leading cause of premature death worldwide. Cancer. 2021;127:3029–30.CrossRefPubMed
3.
go back to reference Zheng RS, Sun KX, Zhang SW, Zeng HM, Zou XN, Chen R, Gu XY, Wei WW. Report of cancer epidemiology in China, 2015. Zhonghua Zhong Liu Za Zhi. 2019;41:19–28.PubMed Zheng RS, Sun KX, Zhang SW, Zeng HM, Zou XN, Chen R, Gu XY, Wei WW. Report of cancer epidemiology in China, 2015. Zhonghua Zhong Liu Za Zhi. 2019;41:19–28.PubMed
4.
go back to reference Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global Cancer statistics 2020: GLOBOCAN estimates of incidence and Mortality Worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71:209–49.CrossRefPubMed Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global Cancer statistics 2020: GLOBOCAN estimates of incidence and Mortality Worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71:209–49.CrossRefPubMed
5.
go back to reference Qiu H, Cao S, Xu R. Cancer incidence, mortality, and burden in China: a time-trend analysis and comparison with the United States and United Kingdom based on the global epidemiological data released in 2020. Cancer Commun (Lond). 2021;41:1037–48.CrossRefPubMed Qiu H, Cao S, Xu R. Cancer incidence, mortality, and burden in China: a time-trend analysis and comparison with the United States and United Kingdom based on the global epidemiological data released in 2020. Cancer Commun (Lond). 2021;41:1037–48.CrossRefPubMed
6.
go back to reference Sun J, Lyu S, Dai Z. The impacts of socioeconomic status and lifestyle on health status of residents: evidence from Chinese General Social Survey data. Int J Health Plann Manage. 2019;34:1097–108.CrossRefPubMed Sun J, Lyu S, Dai Z. The impacts of socioeconomic status and lifestyle on health status of residents: evidence from Chinese General Social Survey data. Int J Health Plann Manage. 2019;34:1097–108.CrossRefPubMed
7.
go back to reference Zhang X, Yizhong Yan1, Li S, Li F, Wan Z. Cancer burden in China from 2006 to 2010. Int J Clin Exp Pathol. 2015;8:13323–13330. Zhang X, Yizhong Yan1, Li S, Li F, Wan Z. Cancer burden in China from 2006 to 2010. Int J Clin Exp Pathol. 2015;8:13323–13330.
8.
go back to reference Wu C, Li M, Meng H, Liu Y, Niu W, Zhou Y, Zhao R, Duan Y, Zeng Z, Li X, Li G, Xiong W, Zhou M. Analysis of status and countermeasures of cancer incidence and mortality in China. Sci China Life Sci. 2019;62:640–7.CrossRefPubMed Wu C, Li M, Meng H, Liu Y, Niu W, Zhou Y, Zhao R, Duan Y, Zeng Z, Li X, Li G, Xiong W, Zhou M. Analysis of status and countermeasures of cancer incidence and mortality in China. Sci China Life Sci. 2019;62:640–7.CrossRefPubMed
11.
go back to reference Cochran WG. Some methods for strengthening the common χ 2 tests. Bioethics. 1954;10:417. Cochran WG. Some methods for strengthening the common χ 2 tests. Bioethics. 1954;10:417.
12.
go back to reference Armitage P. Tests for linear trends in proportions and frequencies. Biometrics. 1955;11:375–0386.CrossRef Armitage P. Tests for linear trends in proportions and frequencies. Biometrics. 1955;11:375–0386.CrossRef
14.
go back to reference Zhou M, Wang H, Zeng X, Yin P, Zhu J, Chen W, Li X, Wang L, Wang L, Liu Y, Liu J, Zhang M, Qi J, Yu S, Afshin A, Gakidou E, Glenn S, Krish VS, Miller-Petrie MK, Mountjoy-Venning WC, Mullany EC, Redford SB, Liu H, Naghavi M, Hay SI, Wang L, Murray CJL, Liang X. Mortality, morbidity, and risk factors in China and its provinces, 1990–2017: a systematic analysis for the global burden of Disease Study 2017. Lancet. 2019;394:1145–58.CrossRefPubMed Zhou M, Wang H, Zeng X, Yin P, Zhu J, Chen W, Li X, Wang L, Wang L, Liu Y, Liu J, Zhang M, Qi J, Yu S, Afshin A, Gakidou E, Glenn S, Krish VS, Miller-Petrie MK, Mountjoy-Venning WC, Mullany EC, Redford SB, Liu H, Naghavi M, Hay SI, Wang L, Murray CJL, Liang X. Mortality, morbidity, and risk factors in China and its provinces, 1990–2017: a systematic analysis for the global burden of Disease Study 2017. Lancet. 2019;394:1145–58.CrossRefPubMed
15.
go back to reference Rui-Mei Feng Y-NZ, Cao S-M. Rui-Hua Xu current cancer situation in China: good or bad news from the 2018 Global Cancer statistics? Cancer Commun (Lond). 2019;39:22.PubMed Rui-Mei Feng Y-NZ, Cao S-M. Rui-Hua Xu current cancer situation in China: good or bad news from the 2018 Global Cancer statistics? Cancer Commun (Lond). 2019;39:22.PubMed
17.
go back to reference Bhandari S, Abdul MKM, Hollabaugh W, Sharma K, Evans DB, Guda N. Decreased trend in hospital mortality from pancreatic cancer despite increase in number of hospital admissions. PLoS ONE. 2018;13:e0199909.CrossRefPubMed Bhandari S, Abdul MKM, Hollabaugh W, Sharma K, Evans DB, Guda N. Decreased trend in hospital mortality from pancreatic cancer despite increase in number of hospital admissions. PLoS ONE. 2018;13:e0199909.CrossRefPubMed
18.
go back to reference Jiang D, Zhang L, Liu W, Ding Y, Yin J, Ren R, Li Q, Chen Y, Shen J, Tan X, Zhang H, Cao G. Trends in cancer mortality in China from 2004 to 2018: a nationwide longitudinal study. Cancer Commun (Lond). 2021;41:1024–36.CrossRefPubMed Jiang D, Zhang L, Liu W, Ding Y, Yin J, Ren R, Li Q, Chen Y, Shen J, Tan X, Zhang H, Cao G. Trends in cancer mortality in China from 2004 to 2018: a nationwide longitudinal study. Cancer Commun (Lond). 2021;41:1024–36.CrossRefPubMed
19.
go back to reference Liu X, Zhou M, Wang F, Mubarik S, Wang Y, Meng R, Shi F, Wen H, Yu C. Secular Trend of Cancer Death and Incidence in 29 Cancer groups in China, 1990–2017: a joinpoint and age–period–cohort analysis. Cancer Manage Res. 2020;12:6221–38.CrossRef Liu X, Zhou M, Wang F, Mubarik S, Wang Y, Meng R, Shi F, Wen H, Yu C. Secular Trend of Cancer Death and Incidence in 29 Cancer groups in China, 1990–2017: a joinpoint and age–period–cohort analysis. Cancer Manage Res. 2020;12:6221–38.CrossRef
20.
go back to reference Galindo-Utrero A, San-Román-Montero JM, Gil-Prieto R, Gil-de-Miguel Á. Trends in hospitalization and in-hospital mortality rates among patients with lung cancer in Spain between 2010 and 2020. BMC Cancer. 2022;22. Galindo-Utrero A, San-Román-Montero JM, Gil-Prieto R, Gil-de-Miguel Á. Trends in hospitalization and in-hospital mortality rates among patients with lung cancer in Spain between 2010 and 2020. BMC Cancer. 2022;22.
21.
go back to reference Liu D, Mehta D, Kaur S, Kumar A, Parikh K, Chawla L, Patel S, Devi A, Saha A. Decreasing mortality and hospitalizations with rising costs related to gastric cancer in the USA: an epidemiological perspective. J Hematol Oncol. 2018;11. Liu D, Mehta D, Kaur S, Kumar A, Parikh K, Chawla L, Patel S, Devi A, Saha A. Decreasing mortality and hospitalizations with rising costs related to gastric cancer in the USA: an epidemiological perspective. J Hematol Oncol. 2018;11.
22.
go back to reference Chen W, Zheng R, Baade PD, Zhang S, Zeng H, Bray F, Jemal A, Yu XQ, He J. Cancer statistics in China, 2015. CA Cancer J Clin. 2016;66:115–32.CrossRefPubMed Chen W, Zheng R, Baade PD, Zhang S, Zeng H, Bray F, Jemal A, Yu XQ, He J. Cancer statistics in China, 2015. CA Cancer J Clin. 2016;66:115–32.CrossRefPubMed
23.
go back to reference Siegel RL, Miller KD, Wagle NS, Jemal A. Cancer statistics, 2023. Cancer J Clin. 2023;73:17–48. Siegel RL, Miller KD, Wagle NS, Jemal A. Cancer statistics, 2023. Cancer J Clin. 2023;73:17–48.
24.
go back to reference Zhang S-Z, Zhang L, Xie L, Sheikh N. Cancer Burden in China during 1990–2019: analysis of the global burden of Disease. Biomed Res Int. 2022;2022:1–21.CrossRef Zhang S-Z, Zhang L, Xie L, Sheikh N. Cancer Burden in China during 1990–2019: analysis of the global burden of Disease. Biomed Res Int. 2022;2022:1–21.CrossRef
25.
go back to reference Zeng H, Chen W, Zheng R, Zhang S, Ji JS, Zou X, Xia C, Sun K, Yang Z, Li H, Wang N, Han R, Liu S, Li H, Mu H, He Y, Xu Y, Fu Z, Zhou Y, Jiang J, Yang Y, Chen J, Wei K, Fan D, Wang J, Fu F, Zhao D, Song G, Chen J, Jiang C, Zhou X, Gu X, Jin F, Li Q, Li Y, Wu T, Yan C, Dong J, Hua Z, Baade P, Bray F, Jemal A, Yu XQ, He J. Changing cancer survival in China during 2003–15: a pooled analysis of 17 population-based cancer registries. The Lancet Global Health. 2018;6:e555–67.CrossRefPubMed Zeng H, Chen W, Zheng R, Zhang S, Ji JS, Zou X, Xia C, Sun K, Yang Z, Li H, Wang N, Han R, Liu S, Li H, Mu H, He Y, Xu Y, Fu Z, Zhou Y, Jiang J, Yang Y, Chen J, Wei K, Fan D, Wang J, Fu F, Zhao D, Song G, Chen J, Jiang C, Zhou X, Gu X, Jin F, Li Q, Li Y, Wu T, Yan C, Dong J, Hua Z, Baade P, Bray F, Jemal A, Yu XQ, He J. Changing cancer survival in China during 2003–15: a pooled analysis of 17 population-based cancer registries. The Lancet Global Health. 2018;6:e555–67.CrossRefPubMed
26.
go back to reference Shain M, Roemer MI. Hospital costs relate to the supply of beds. Mod Hosp. 1959;92 4:71–3passim. Shain M, Roemer MI. Hospital costs relate to the supply of beds. Mod Hosp. 1959;92 4:71–3passim.
27.
go back to reference Fielding R, Delamater PL, Messina JP, Grady SC, WinklerPrins V, Shortridge AM. Do more Hospital beds lead to higher hospitalization rates? A spatial examination of Roemer’s Law. PLoS ONE. 2013;8. Fielding R, Delamater PL, Messina JP, Grady SC, WinklerPrins V, Shortridge AM. Do more Hospital beds lead to higher hospitalization rates? A spatial examination of Roemer’s Law. PLoS ONE. 2013;8.
28.
go back to reference Mahumud RA, Alam K, Dunn J, Gow J. Emerging cancer incidence, mortality, hospitalisation and associated burden among Australian cancer patients, 1982–2014: an incidence-based approach in terms of trends, determinants and inequality. BMJ Open. 2019;9. Mahumud RA, Alam K, Dunn J, Gow J. Emerging cancer incidence, mortality, hospitalisation and associated burden among Australian cancer patients, 1982–2014: an incidence-based approach in terms of trends, determinants and inequality. BMJ Open. 2019;9.
29.
go back to reference Rishi KWK, Yeh RW. Did this health care policy do harm? N Y Times. 2018. Rishi KWK, Yeh RW. Did this health care policy do harm? N Y Times. 2018.
30.
go back to reference Xu R, Wu L, Liu Y, Ye Y, Mu T, Xu C, Yuan H. Evaluation of the impact of the COVID-19 pandemic on health service utilization in China: a study using auto-regressive integrated moving average model. Front Public Health. 2023;11. Xu R, Wu L, Liu Y, Ye Y, Mu T, Xu C, Yuan H. Evaluation of the impact of the COVID-19 pandemic on health service utilization in China: a study using auto-regressive integrated moving average model. Front Public Health. 2023;11.
31.
go back to reference Sanchez JC, García B, Ruano A, Blanco M, Ibarguren BCSd, Méndez M, Ramos-Vegue AJ, Morito AM, Aguado R, Provencio-Pulla M. Impact of COVID19 pandemic on the hospitalization burden of cancer patients: results of a quasi-experimental study. J Clin Oncol. 2021. Sanchez JC, García B, Ruano A, Blanco M, Ibarguren BCSd, Méndez M, Ramos-Vegue AJ, Morito AM, Aguado R, Provencio-Pulla M. Impact of COVID19 pandemic on the hospitalization burden of cancer patients: results of a quasi-experimental study. J Clin Oncol. 2021.
32.
go back to reference Howarth A, Munro M, Theodorou A, Mills PR. Trends in healthcare utilisation during COVID-19: a longitudinal study from the UK. BMJ Open. 2021;11. Howarth A, Munro M, Theodorou A, Mills PR. Trends in healthcare utilisation during COVID-19: a longitudinal study from the UK. BMJ Open. 2021;11.
33.
go back to reference Kotiso M, Qirbi N, Al-Shabi K, Vuolo E, Al-Waleedi A, Naiene J, Senga M, Khalil M, Basaleem H, Alhidary A. Impact of the COVID-19 pandemic on the utilisation of health services at public hospitals in Yemen: a retrospective comparative study. BMJ Open. 2022;12. Kotiso M, Qirbi N, Al-Shabi K, Vuolo E, Al-Waleedi A, Naiene J, Senga M, Khalil M, Basaleem H, Alhidary A. Impact of the COVID-19 pandemic on the utilisation of health services at public hospitals in Yemen: a retrospective comparative study. BMJ Open. 2022;12.
34.
go back to reference Wang H, Zhang L. Risk of COVID-19 for patients with cancer. Lancet Oncol. 2020;21. Wang H, Zhang L. Risk of COVID-19 for patients with cancer. Lancet Oncol. 2020;21.
35.
go back to reference Dahiya DS, Inamdar S, Perisetti A, Kichloo A, Singh A, Solanki S, Solanki D, Al-Haddad M. Decreasing length of stay and inpatient mortality associated with pancreatic cancer hospitalizations: a United States national survey from 2008 to 2017. Pancreatology. 2022;22:590–7.CrossRefPubMed Dahiya DS, Inamdar S, Perisetti A, Kichloo A, Singh A, Solanki S, Solanki D, Al-Haddad M. Decreasing length of stay and inpatient mortality associated with pancreatic cancer hospitalizations: a United States national survey from 2008 to 2017. Pancreatology. 2022;22:590–7.CrossRefPubMed
36.
37.
go back to reference Xin Wang AZ, Xin He H, Jiang. Integration of rural and urban healthcare insurance schemes in China: an empirical research. BMC Health Serv Res. 2014;14:142.CrossRefPubMed Xin Wang AZ, Xin He H, Jiang. Integration of rural and urban healthcare insurance schemes in China: an empirical research. BMC Health Serv Res. 2014;14:142.CrossRefPubMed
Metadata
Title
Temporal trend in hospitalizations for malignant neoplasm and benign neoplasm: a nationwide study, China, 2004–2020
Authors
Xinqiang Zhang
Yuanyuan Li
Guifang Zhang
Changsheng Ma
Bo Liu
Yong Yin
Publication date
01-12-2024
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2024
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/s12885-024-11866-x

Other articles of this Issue 1/2024

BMC Cancer 1/2024 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine